TY - JOUR
T1 - Plasma level of club-cell (CC-16) predicts outcome in amyotrophic lateral sclerosis
AU - Pronto-Laborinho, A. C.
AU - Gromicho, M.
AU - Pereira, M.
AU - Pinto, S.
AU - Barros, M. do A.
AU - Swash, M.
AU - de Carvalho, M.
N1 - Publisher Copyright:
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2018/2
Y1 - 2018/2
N2 - Objectives: The club cell protein (CC-16) is a biomarker associated with respiratory distress and pulmonary inflammation. We evaluated CC-16 as a candidate biomarker for respiratory failure in amyotrophic lateral sclerosis (ALS). Materials and Methods: We studied 81 ALS patients and 30 matched controls. We used an ALS-related measure of functional capacity, and tested forced vital capacity (FVC) and the amplitude of the diaphragmatic response by phrenic nerve stimulation (PhrenAmpl). Plasma CC-16 levels were measured in venous blood. Kaplan-Meier survival curves were plotted to evaluate risk to non-invasive ventilation and death in patients with abnormal CC-16 levels. Results: CC-16 levels were significantly raised in ALS patients (10.56 ng/mL ± 6.84 vs 8.34 ng/mL ± 3.10, P =.02), and in 17% of them, CC-16 level was above the upper cutoff value (mean + 2.5SD). CC-16 levels did not correlate with age, onset region, disease duration, functional status, FVC, and PhrenAmpl. In patients with increased CC-16 level, the risk of non-invasive was greater in the following 6 months (P =.01) and tended to have higher mortality in the following 30 months (P =.07). Conclusions: We propose that increased CC-16 levels is a marker of lung inflammatory response that associated with ventilatory insufficiency are related to impending respiratory failure, not fully predicted by conventional respiratory tests. The latter are limited by the moment of testing.
AB - Objectives: The club cell protein (CC-16) is a biomarker associated with respiratory distress and pulmonary inflammation. We evaluated CC-16 as a candidate biomarker for respiratory failure in amyotrophic lateral sclerosis (ALS). Materials and Methods: We studied 81 ALS patients and 30 matched controls. We used an ALS-related measure of functional capacity, and tested forced vital capacity (FVC) and the amplitude of the diaphragmatic response by phrenic nerve stimulation (PhrenAmpl). Plasma CC-16 levels were measured in venous blood. Kaplan-Meier survival curves were plotted to evaluate risk to non-invasive ventilation and death in patients with abnormal CC-16 levels. Results: CC-16 levels were significantly raised in ALS patients (10.56 ng/mL ± 6.84 vs 8.34 ng/mL ± 3.10, P =.02), and in 17% of them, CC-16 level was above the upper cutoff value (mean + 2.5SD). CC-16 levels did not correlate with age, onset region, disease duration, functional status, FVC, and PhrenAmpl. In patients with increased CC-16 level, the risk of non-invasive was greater in the following 6 months (P =.01) and tended to have higher mortality in the following 30 months (P =.07). Conclusions: We propose that increased CC-16 levels is a marker of lung inflammatory response that associated with ventilatory insufficiency are related to impending respiratory failure, not fully predicted by conventional respiratory tests. The latter are limited by the moment of testing.
KW - amyotrophic lateral sclerosis
KW - biomarker
KW - human club cell CC-16
KW - respiratory function
KW - respiratory insufficiency
UR - http://www.scopus.com/inward/record.url?scp=85030464866&partnerID=8YFLogxK
U2 - 10.1111/ane.12851
DO - 10.1111/ane.12851
M3 - Article
C2 - 28967121
AN - SCOPUS:85030464866
SN - 0001-6314
VL - 137
SP - 233
EP - 237
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
IS - 2
ER -